Moderna Inc
(MIL:1MRNA)
€
38.165
-0.445 (-1.15%)
Market Cap: 14.61 Bil
Enterprise Value: 9.32 Bil
PE Ratio: 0
PB Ratio: 1.30
GF Score: 44/100 Moderna Inc at Goldman Sachs Global Healthcare Conference Transcript
Jun 14, 2022 / 04:20PM GMT
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP
Good morning, everyone. Really pleased to have Moderna here with us. We have Lavina Talukdar, Head of IR. With that, Lavina, I'm going to turn it over to you if you have any opening comments, so we can just jump into Q&A.
Lavina Talukdar
Moderna, Inc. - Senior VP & Head of IR
Thank you, Salveen, for having us here at the conference. And I would actually like to open it up to Q&A.
Questions & Answers
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP
Perfect. So let's just start here with the data that you just presented, the Phase II/III data of the bivalent booster. Just describe that data to us and what your discussions with regulators have been and what the path forward is to getting it on to market.
Lavina Talukdar
Moderna, Inc. - Senior VP & Head of IR
Great question. Thank you for that. So we just showed the Phase II/III data just last week.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot